Gemphire Therapeutics (GEMP) Covered By Yet Another Research Firm

May 17, 2018 - By Jimmy Baldridge

Why Has Raymond James Given Gemphire Therapeutics (GEMP) a $22.0000 Price Target

In an analyst note sent to investors and clients today, Raymond James analysts began Gemphire Therapeutics (GEMP) coverage with Buy rating, and a $22.0000 target.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Ratings Coverage

Among 3 analysts covering Gemphire Therapeutics (GEMP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Gemphire Therapeutics has $30.0 highest and $22 lowest target. $26.67’s average target is 318.68% above currents $6.37 stock price. Gemphire Therapeutics had 3 analyst reports since December 22, 2017 according to SRatingsIntel. H.C. Wainwright maintained Gemphire Therapeutics Inc. (NASDAQ:GEMP) on Friday, January 26 with “Buy” rating.

The stock increased 0.63% or $0.04 during the last trading session, reaching $6.37. About 303,299 shares traded or 173.75% up from the average. Gemphire Therapeutics Inc. (GEMP) has declined 45.18% since May 18, 2017 and is downtrending. It has underperformed by 56.73% the S&P500.

Analysts await Gemphire Therapeutics Inc. (NASDAQ:GEMP) to report earnings on August, 13. They expect $-0.54 earnings per share, up 27.03 % or $0.20 from last year’s $-0.74 per share. After $-0.58 actual earnings per share reported by Gemphire Therapeutics Inc. for the previous quarter, Wall Street now forecasts -6.90 % EPS growth.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis . The company has market cap of $90.66 million. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. It currently has negative earnings.

More notable recent Gemphire Therapeutics Inc. (NASDAQ:GEMP) news were published by: Benzinga.com which released: “40 Stocks Moving In Wednesday’s Mid-Day Session” on May 16, 2018, also Nasdaq.com with their article: “Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update” published on May 08, 2018, Benzinga.com published: “Benzinga’s Top Upgrades, Downgrades For May 16, 2018” on May 16, 2018. More interesting news about Gemphire Therapeutics Inc. (NASDAQ:GEMP) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on May 16, 2018 as well as Benzinga.com‘s news article titled: “41 Biggest Movers From Yesterday” with publication date: May 17, 2018.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.